Table 1 Sero-prevalence in children aged 1–15 years by antigen, geographical region, and transmission season. Mean sero-prevalence estimates are shown for the West Coast Region (WCR) for July 2013 and December 2013, and the Upper River Region (URR) for July 2013, December 2013, April 2014, and December 2014. Mean and 95% confidence intervals (parentheses) are shown as percentages
A. Ages 1–15 years sero-prevalence (95% CI)—short-lived antibody responses | |||||
| Â | Etramp5.Ag1 | GEXP18 | HSP40.Ag1 | Rh2.2030 | EBA175 |
 West Coast Region (WCR) | |||||
  July 2013 (n = 309) | 3.2% (1.9–4.5) | 7.5% (5.6–9.4) | 3.8% (2.4–5.1) | 1.5% (0.6–2.4) | 1.7% (0.8–2.6) |
  December 2013 (n = 315) | 8.0% (6.2–9.9) | 9.8% (7.7–11.8) | 4.6% (3.1–6.1) | 1.9% (1.0–2.9) | 1.1% (0.4–1.9) |
 Upper River Region (URR) | |||||
  July 2013 (n = 431) | 5.6% (4.2–7.0) | 16.4% (14.1–18.7) | 7.2% (5.5–8.8) | 6.8% (5.2–8.3) | 5.3% (3.9–6.7) |
  December 2013 (n = 387) | 18.5% (16.1–20.9) | 22.5% (20.0–25.1) | 14.4% (12.2–16.5) | 17.1% (14.8–19.4) | 10.5% (8.7–12.4) |
  April 2014 (n = 489) | 13.9% (12.0–15.8) | 20.7% (18.5–22.9) | 14.1% (12.1–16.0) | 14.3% (12.4–16.2) | 9.3% (7.7–10.9) |
  December 2014 (n = 434) | 15.4% (13.2–17.6) | 25.5% (22.9–28.1) | 16.0% (13.8–18.2) | 13.2% (11.2–15.3) | 8.6% (6.9–10.3) |
B. Ages 1–15 years (95% CI)—long-lived antibody responses | |||||
| Â | PfMSP119 | PfAMA1 | PfGLURP.R2 | Â | Â |
 West Coast Region (WCR) | |||||
  July 2013 (n = 309) | 1.7% (0.8–2.6) | 3.8% (2.4–5.1) | 3.2% (1.9–4.5) |  |  |
  December 2013 (n = 315) | 4.8% (3.3–6.3) | 4.0% (2.7–5.4) | 6.1% (4.5–7.8) |  |  |
 Upper River Region (URR) |  | ||||
  July 2013 (n = 431) | 3.4% (2.2–4.5) | 14.4% (12.2–16.6) | 12.1% (10.1–14.1) |  |  |
  December 2013 (n = 387) | 12.8% (10.7–14.8) | 22.5% (20.0–25.1) | 20.8% (18.3–23.3) |  |  |
  April 2014 (n = 489) | 8.5% (7.0–10.1) | 19.2% (17.0–21.4) | 18.7% (16.5–20.8) |  |  |
  December 2014 (n = 434) | 9.3% (7.5–11.0) | 18.0% (15.7–20.3) | 16.5% (14.3–18.7) |  |  |